High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

Leukemia

Volumn 19, Issue 6, 2005, Pages 978-983

  Schlenk, Richard F ^a   Germing, U ^b   Hartmann, F ^c   Glasmacher, A ^d   Fischer, I T ^e   del Valle y Fuentes, F ^f   Gotze K ^g   Pralle, H ^h   Nerl, C ⁱ   Salwender, H ^j   Grimminger, W ^k   Petzer, A ^l   Hensel, M ^m   Benner, A ⁿ   Zick, L ^a   Dohner K ^a   Frohling S ^a   Dohner H ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^f II Medizinische Klinik   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁱ Klinikum Schwabing   (Germany)

^j ASKLEPIOS KLINIK ALTONA   (Germany)

^k KLINIKUM STUTTGART   (Germany)

^l UNIVERSITY OF INNSBRUCK   (Austria)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

Activating FLT3 mutations; Acute promyelocytic leukemia; Additional chromosomal aberrations; High dose cytarabine

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; PROTEIN TYROSINE KINASE; RETINOIC ACID; AIDA PROTOCOL; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; MAC CHEMOTHERAPY PROTOCOL; ONCOPROTEIN;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEILITIS; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE MARKER; DRUG MEGADOSE; FEMALE; HEART FAILURE; HUMAN; INFECTION; KERATOCONJUNCTIVITIS; LEUKOCYTE COUNT; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; THROMBOCYTOPENIA; THROMBOEMBOLISM; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; REMISSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IDARUBICIN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; TRETINOIN;

EID: 20844433082     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403766     Document Type: Article

References (38)

1. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all- trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
2. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
3. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
4. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
5. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14: 1371-1377.
6. Chen ZX, Xue YQ Zhang R, Tao RF, Xia XM, Li C et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
7. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
8. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717-1728.
9. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483-490.
10. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362-1370.
11. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukaemia treated with all- trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93: 4131-4143.
12. Haferlach T, Gassmann W, Loffler H, Jurgensen C, Noak J, Ludwig WD et al. Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group. Ann Hematol 1993; 66: 165-170.
13. Tallman MS Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup Protocol. Blood 2002; 100: 4298-4302.
14. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288.
15. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447-1452.
16. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002; 16: 2185-2189.
17. Shih LY, Kuo MC, Liang DC, Huang CF, Lin TL, Wu JH et al. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 2003; 98: 1206-1216.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 620-625.
19. Mitelman F (ed) ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger, 1995.
20. Fischer K, Scholl C, Sàlat J, Fröhling S, Schlenk R, Bentz M et al. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood 1996; 88: 3962-3971.
21. Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Döhner H et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 2002; 20: 2480-2485.
22. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm (AMLSG ULM). Blood 2002; 100: 4372-4380.
23. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398.
24. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
25. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986; 5: 255-260.
26. Kaplan EL, Meier P. Non-parametric estimation form incomplete observation. J Am Stat Assoc 1958; 47: 457-481.
27. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer Verlag, 2000.
28. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
29. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972; 34: 187-220.
30. Harrell FE. Regression Modelling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer Verlag, 2001.
31. Ihaka R, Gentleman R. R: A Language for data analysis and graphics. J Comput Graphical Stat 1996; 5: 299-314.
32. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al. Risk-adapted treatment of acute promyelocytic leukemia with all- trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243.
33. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
34. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96: 314-321.
35. Hernandez JM, Martin G, Gutierrez NC, Cervera J, Ferro MT, Calasanz MJ et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001; 86: 807-813.
36. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al., European APL Group. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000; 111: 801-806.
37. Wan TS, Ma SK, Au WY, Liu HS, Chan JC, Chan LC. Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia. Cancer Genet Cytogenet 2003; 140: 170-173.
38. Xu L, Zhao WL, Xiong SM, Su XY, Zhao M, Wang C et al. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia 2001; 15: 1359-1368.